Xiaomei Ma, PhD
Professor of Epidemiology (Chronic Diseases)DownloadHi-Res Photo
Cards
Additional Titles
Co-Leader, Cancer Prevention and Control
Contact Info
Chronic Disease Epidemiology
PO Box 208034, 60 College Street
New Haven, CT 06520-8034
United States
About
Copy Link
Titles
Professor of Epidemiology (Chronic Diseases)
Co-Leader, Cancer Prevention and Control
Biography
Dr. Ma is Professor of Epidemiology at the Yale School of Public Health, and Co-Leader of the Cancer Prevention and Control Research Program at the Yale Comprehensive Cancer Center, Yale School of Medicine. She studies the etiology and health outcomes of different types of cancer, with a focus on pediatric cancer and malignancies of the hematopoietic system (e.g., leukemia, lymphoma, myelodysplastic syndromes, and myeloproliferative neoplasms). Her research has addressed the impact of immunological factors, chemical exposures, and genetic characteristics on the risk of cancer. In addition, she has assessed the patterns of care and cost implications of cancer screening and treatment in older adults.
Last Updated on May 09, 2025.
Appointments
Chronic Disease Epidemiology
ProfessorPrimary
Other Departments & Organizations
- All Institutions
- Cancer Prevention and Control
- Chronic Disease Epidemiology
- Climate Change and Health
- COPPER Center
- K12 Calabresi Immuno-Oncology Training Program (IOTP)
- Yale Cancer Center
- Yale School of Public Health
- Yale Ventures
Education & Training
- PhD
- University of California at Berkeley (2001)
Research
Copy Link
Overview
Medical Research Interests
Chronic Disease; Epidemiology; Leukemia; Lymphoma; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasms
Public Health Interests
Health Policy; Chronic Diseases; Cancer; Aging; Maternal & Child Health
ORCID
0000-0001-9472-8032
Research at a Glance
Yale Co-Authors
Frequent collaborators of Xiaomei Ma's published research.
Publications Timeline
A big-picture view of Xiaomei Ma's research output by year.
Research Interests
Research topics Xiaomei Ma is interested in exploring.
Rong Wang, PhD
Amer Zeidan, MBBS, MD
Nikolai Podoltsev, MD, PhD
Scott Huntington, MD, MPH, MSc
Cary P Gross, MD
Michael S. Leapman, MD, MHS
319Publications
9,694Citations
Myelodysplastic Syndromes
Neoplasms
Leukemia
Myeloproliferative Disorders
Chronic Disease
Lymphoma
Publications
2026
Response by Chu et al to Letter Regarding Article, “Joint Exposure to Ozone and Temperature and Acute Myocardial Infarction Among Adults Aged 18 to 64 Years in the United States”
Chu L, Ma X, Chen K. Response by Chu et al to Letter Regarding Article, “Joint Exposure to Ozone and Temperature and Acute Myocardial Infarction Among Adults Aged 18 to 64 Years in the United States”. Circulation 2026, 153: e914-e915. PMID: 41802023, DOI: 10.1161/circulationaha.125.078382.Peer-Reviewed Original ResearchAssociation between genomic classifier scores and initial management of localized prostate cancer in a population-based cohort in the United States.
Leapman M, Wang R, Sprenkle P, Kim I, Dinan M, Gross C, Ma X. Association between genomic classifier scores and initial management of localized prostate cancer in a population-based cohort in the United States. Journal Of Clinical Oncology 2026, 44: 350-350. DOI: 10.1200/jco.2026.44.7_suppl.350.Peer-Reviewed Original ResearchConceptsIntermediate-risk prostate cancerIntermediate-risk diseaseProstate cancerActive surveillanceAssociated with lower oddsClinical dataGC scoresGenomic classifierManagement of localized prostate cancerLow-risk diseaseLocalized prostate cancerIntermediate-risk groupLower oddsGenomic classifier scoresProstate cancer diagnosisLow-risk groupClinical risk groupsMultivariate logistic regressionPopulation-based cohortPopulation-based linkageRisk diseaseInitial treatmentPrognostic informationInitial managementPathological covariatesAdoption and Regional Variation of Prostate-Specific Membrane Antigen Positron Emission Tomography in the United States.
Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Spilberg G, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Rivera D, Kluetz P, Karnes R, Dinan M, Mitchell A, Kunst N, Wang S, Ma X, Gross C. Adoption and Regional Variation of Prostate-Specific Membrane Antigen Positron Emission Tomography in the United States. JCO Oncology Practice 2026, op2500617. PMID: 41632928, DOI: 10.1200/op-25-00617.Peer-Reviewed Original ResearchAltmetricConceptsProstate-specific membrane antigen positron emission tomographyPSMA-PETProstate cancerPositron emission tomographyPET imagingNational utilization patternsIncident prostate cancer casesLong-term clinical benefitPSMA PET imagingEmission tomographyProstate cancer casesEvidence of diagnostic accuracyCross-sectional studyClinical benefitCancer casesEligible patientsDiagnostic accuracyProstateInsurance beneficiariesCancerClinical practiceHealth care characteristicsProportion of individualsAdministrative claimsTomographySmoldering multiple myeloma in the United States: a population-based analysis
Wang S, Wang R, Schoen M, Huber J, Feuer E, Ruhl J, Neparidze N, Ma X, Davidoff A, Chang S. Smoldering multiple myeloma in the United States: a population-based analysis. Blood Advances 2026, 10: 661-664. PMID: 41213002, PMCID: PMC12870838, DOI: 10.1182/bloodadvances.2025017817.Peer-Reviewed Original ResearchAltmetricResidential proximity to active and abandoned oil and gas development and risk of childhood Ewing sarcoma in California
Clark C, Johnson N, Wang R, Stewart E, Spector L, Wiemels J, Metayer C, Deziel N, Ma X. Residential proximity to active and abandoned oil and gas development and risk of childhood Ewing sarcoma in California. Environmental Health 2026, 25: 12. PMID: 41535920, PMCID: PMC12888232, DOI: 10.1186/s12940-025-01259-3.Peer-Reviewed Original ResearchAltmetricConceptsSarcoma riskControls frequency-matched to casesHispanic childrenFrequency-matched to casesOdds ratioCalifornia Cancer RegistryClustering of cancerConfidence intervalsPediatric cancer riskNon-Hispanic childrenMultivariate logistic regressionBirth addressCancer RegistryHealth outcomesEwing sarcomaNon-HispanicCancer riskChildhood cancerResidential proximityBirth yearUnexposed childrenLogistic regressionMethodsThis studyExposure disparitiesDiagnosis of Ewing's sarcomaTrends in Smoldering Myeloma Incidence in the United States From Cancer Registries, 2012–2022
Wang R, Davidoff A, Schoen M, Huber J, Feuer E, Ruhl J, Neparidze N, Ma X, Chang S, Wang S. Trends in Smoldering Myeloma Incidence in the United States From Cancer Registries, 2012–2022. American Journal Of Hematology 2026, 101: 923-925. PMID: 41528052, PMCID: PMC12912868, DOI: 10.1002/ajh.70202.Peer-Reviewed Original ResearchAltmetric
2025
Impact of metformin on the incidence of thrombotic events in older patients with polycythemia vera and essential thrombocythemia in the United States
Stempel J, Wang R, Shallis R, Mendez L, Bewersdorf J, Stahl M, Zeidan A, Ma X, Podoltsev N. Impact of metformin on the incidence of thrombotic events in older patients with polycythemia vera and essential thrombocythemia in the United States. Blood 2025, 146: 6392-6392. DOI: 10.1182/blood-2025-6392.Peer-Reviewed Original ResearchAltmetricConceptsHistory of thrombosisDiagnosis of DMMetformin non-usersMyeloproliferative neoplasmsMetformin usersThrombotic eventsThrombotic riskPolycythemia veraMetformin useEssential thrombocythemiaOlder ptsSevere DMDiabetes mellitusImpact of metforminNo significant associationDM severityFollow-upPhiladelphia chromosome negative myeloproliferative neoplasmsPre-existing cardiovascular risk factorsHistory of thrombotic eventsNon-usersIncidence rate of thrombosisIncidence of thrombotic eventsDevelopment of myeloproliferative neoplasmsIncidence rateTreatment initiation and first line tyrosine kinase inhibitor (TKI) selection for older patients with newly diagnosed chronic myeloid leukemia (CML) in the United States (US) before and after the introduction of generic imatinib (GE-IMA)
Wang R, Stempel J, Shallis R, Bewersdorf J, Mendez L, Stahl M, Zeidan A, Ma X, Podoltsev N. Treatment initiation and first line tyrosine kinase inhibitor (TKI) selection for older patients with newly diagnosed chronic myeloid leukemia (CML) in the United States (US) before and after the introduction of generic imatinib (GE-IMA). Blood 2025, 146: 6393-6393. DOI: 10.1182/blood-2025-6393.Peer-Reviewed Original ResearchConceptsMedian time to initiationChronic myeloid leukemiaTime to initiationMonths of diagnosisRetrospective cohort studyTreatment initiationAssociated with higher likelihoodTKI therapyOlder ptsCML diagnosisFollow-upOlder patientsFirst-generation TKI imatinibChronic myeloid leukemia diagnosisEnd Results Medicare-linked databaseMultivariate Cox proportional hazards modelLow-income subsidySecond-generation TKIsMedicare-linked databaseAge of diagnosisCox proportional hazards modelsPre-GProportional hazards modelGeneric imatinibImatinib usersAcute myeloid leukemia (AML) after myeloproliferative neoplasm (MPN): Real-world outcomes in the new AML treatment era
Bewersdorf J, Wang R, Mendez L, Stahl M, Zeidan A, Ma X, Podoltsev N. Acute myeloid leukemia (AML) after myeloproliferative neoplasm (MPN): Real-world outcomes in the new AML treatment era. Blood 2025, 146: 721. DOI: 10.1182/blood-2025-721.Peer-Reviewed Original ResearchConceptsPost-MPN acute myeloid leukemiaAcute myeloid leukemiaOverall survivalAllo-HCTMyeloproliferative neoplasmsMedian OSTreatment eraBridging treatmentVariable risk of progression to acute myeloid leukemiaRisk of progression to acute myeloid leukemiaProgression to acute myeloid leukemiaElectronic health record-derivedAssociated with better OSAllogeneic hematopoietic cell transplantationAbstract Myeloproliferative neoplasmsAssociated with male sexMedian overall survivalImprovement of OSVariable riskHematopoietic cell transplantationBaseline performance statusLimited treatment optionsMinority of patientsCox regression analysisLower-intensity therapiesThe impact of Indigenous American-like ancestry on the risk of acute lymphoblastic leukemia in Hispanic/Latino children
Langie J, Chan T, Yang W, Kang A, Morimoto L, Stram D, Mancuso N, Ma X, Metayer C, Lupo P, Rabin K, Scheurer M, Wiemels J, Yang J, de Smith A, Chiang C. The impact of Indigenous American-like ancestry on the risk of acute lymphoblastic leukemia in Hispanic/Latino children. Human Genetics And Genomics Advances 2025, 7: 100534. PMID: 41261530, PMCID: PMC12664375, DOI: 10.1016/j.xhgg.2025.100534.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsAcute lymphoblastic leukemia riskRisk of acute lymphoblastic leukemiaHispanic/Latino childrenNon-genetic correlationsHighest incidences of acute lymphoblastic leukemiaAssociated with ALL riskGenetic etiologyGenetic etiology of diseaseRisk allelesGenetic risk lociFrequency of risk allelesIncidence of acute lymphoblastic leukemiaAdmixture mappingHispanic/Latino individualsAssociation signalsRisk lociRacial/ethnic groupsChildhood cancerSocioeconomic indicatorsGenetic ancestryHigher incidenceAcute lymphoblastic leukemiaGenetic variantsALL riskEffect size
Academic Achievements & Community Involvement
Copy Link
News
Copy Link
News
- January 27, 2026
Epidemiologist Dr. Magdalena Cerdá joins YSPH as Chair of the Department of Chronic Disease Epidemiology
- October 28, 2025Source: Yale News
Study Reveals Demographic Disparities in Uptake of Colorectal Cancer Screenings
- September 10, 2025Source: STAT
Risk of dying from chronic disease in the U.S. declined, but there are caveats, study says
- June 03, 2025Source: Yale News
Insights & Outcomes: Star Music, Kavli Kudos, and Summertime Heart Risks
Get In Touch
Copy Link
Contacts
Email
Academic Office Number
Office Fax Number
Mailing Address
Chronic Disease Epidemiology
PO Box 208034, 60 College Street
New Haven, CT 06520-8034
United States
Locations
60 College Street
Academic Office
Ste 406
New Haven, CT 06510